专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021089821A1 IRON-SCORE AND IN VITRO METHOD FOR IDENTIFYING MANTLE CELL LYMPHOMA (MCL) SUBJECTS AND THERAPEUTIC USES AND METHODS 审中-公开
公开(公告)号：WO2021089821A1
公开(公告)日：2021-05-14
申请号：PCT/EP2020/081352
申请日：2020-11-06
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE MONTPELLIER , INSTITUT CURIE
发明人： MOREAUX, Jérôme , RODRIGUEZ, Raphaël , DEVIN, Julie , BRET, Caroline , CANEQUE COBO, Tatiana
IPC分类号： C12Q1/6886
摘要： The invention relates to the use of an iron-score based on the expression level of at least 1 gene, in particular at least 3, preferably at least 5, and even preferably 8 genes selected in the group consisting of APEX1, TFRC, HIF1A, ABCG2, SCARA3, IREB2, SFXN4 and SLC39A14 involved in the iron metabolism, as a prognosis marker in subjects having MCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

2. 发明申请

WO2022234040A1 NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN MULTIPLE MYELOMA (MM) 审中-公开
公开(公告)号：WO2022234040A1
公开(公告)日：2022-11-10
申请号：PCT/EP2022/062202
申请日：2022-05-05
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人： RODRIGUEZ, Raphaël , MOREAUX, Jérôme , BRET, Caroline , DEVIN, Julie , CANEQUE COBO, Tatiana
IPC分类号： A61K31/198 , A61K31/35 , A61K31/454 , A61K38/07 , A61P35/02
摘要： The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: (F), wherein W, X, Y and Z are as defined, for use in the treatment of Multiple Myeloma (MM).

3. 发明申请

WO2021089819A1 IRON-SCORE AND IN VITRO METHOD FOR IDENTIFYING HIGH RISK DLBCL SUBJECTS AND THERAPEUTIC USES AND METHODS 审中-公开
公开(公告)号：WO2021089819A1
公开(公告)日：2021-05-14
申请号：PCT/EP2020/081349
申请日：2020-11-06
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE MONTPELLIER , INSTITUT CURIE
发明人： MOREAUX, Jérôme , RODRIGUEZ, Raphaël , DEVIN, Julie , BRET, Caroline , CANEQUE COBO, Tatiana
IPC分类号： C12Q1/6886
摘要： The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

4. 发明申请

WO2016012630A1 METHODS FOR PREDICTING RESPONSE TO DNA REPAIR PATHWAY INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA 审中-公开
标题翻译：用于预测大量B细胞淋巴瘤中DNA修复途径抑制剂的反应方法
公开(公告)号：WO2016012630A1
公开(公告)日：2016-01-28
申请号：PCT/EP2015/067174
申请日：2015-07-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE MONTPELLIER , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： MOREAUX, Jérôme , CARTRON, Guillaume , BRET, Caroline , CONSTANTINOU, Angelos , PASERO, Philippe
IPC分类号： C12Q1/68 , G06F19/18 , G06F19/20 , G06F19/24
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G06F19/00 , G06F19/18 , G06F19/20 , G06F19/24 , G16H50/30
摘要： The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein βi represent the regression β coefficient reference value for the gene Gi and C i = 1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci = -1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARS R v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARS R or concluding that the patient will not respond to the treatment when the DNARS score is lower than the predetermined reference value DNARS R .
摘要翻译：本发明涉及一种检测是否患有弓形B细胞淋巴瘤的患者是否对DNA修复途径抑制剂有反应的方法，包括：i）确定从表A中选出的若干基因Gi-Gn的表达水平（ELi）在从所述患者获得的生物样品中比较在步骤i）确定的表达水平（ELi）与预定参考水平（ELRi）iii）通过下式（I）计算DNA修复评分，其中βi表示回归β系数如果基因Gi（ELi）的表达高于预定参考水平（ELRi），则基因Gi和Ci = 1的参考值，如果基因（ELi）的表达低于或等于预定参考水平（ELRi）iv）将在步骤iii）确定的分数DNARS与预定参考值DNARSR v）进行比较，并得出当DNARS评分高于预测值时患者将对治疗作出响应开采参考值DNARSR或结论当DNARS评分低于预定参考值DNARSR时患者不会对治疗作出反应。

5. 发明申请

WO2017140743A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MULTIPLE MYELOMA 审中-公开
标题翻译：用于治疗多发性骨髓瘤的方法和药物组合物
公开(公告)号：WO2017140743A1
公开(公告)日：2017-08-24
申请号：PCT/EP2017/053435
申请日：2017-02-15
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE MONTPELLIER , INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： MOREAUX, Jérôme , JULIEN, Eric , IZARD, Fanny , GRIMAUD, Charlotte , HERVIOU, Laurie
IPC分类号： A61K31/517 , A61K31/192 , A61P35/00
CPC分类号： A61K31/517 , A61K31/192
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of multiple myeloma. In particular, the present invention relates to a method of treating multiple myeloma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a SETD8 inhibitor.
摘要翻译：本发明涉及用于治疗多发性骨髓瘤的方法和药物组合物。具体而言，本发明涉及治疗有此需要的患者中的多发性骨髓瘤的方法，其包括向患者施用治疗有效量的SETD8抑制剂。

6. 发明申请

WO2015140321A1 METHODS FOR PREDICTING RESPONSE TO HDACI/DNMTI COMBINATION IN MULTIPLE MYELOMA 审中-公开
标题翻译：多重MYELOMA对HDACI / DNMTI组合的预测方法
公开(公告)号：WO2015140321A1
公开(公告)日：2015-09-24
申请号：PCT/EP2015/055992
申请日：2015-03-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE MONTPELLIER , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
发明人： MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号： C12Q1/68 , A61K31/7068
CPC分类号： C12Q1/6886 , A61K31/165 , A61K31/167 , A61K31/706 , A61K45/06 , C12Q2600/106 , C12Q2600/158 , G06F19/00 , G06F19/24 , G06F19/325 , G16H10/20 , G16H50/30 , A61K2300/00
摘要： The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G 1 -G n selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein βi represent the regression β coefficient reference value for the gene Gi and Ci = 1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci = -1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMS R v) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMS R or concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMS R .
摘要翻译：本发明涉及一种测试患有多发性骨髓瘤的患者是否对由至少一种组蛋白脱乙酰酶抑制剂（HDACi）与至少一种DNA甲基转移酶抑制剂（DNMTi）组成的组合治疗反应，该方法包括：i）确定从从所述患者获得的生物样品中从表A中选出的若干基因G1-Gn的表达水平（ELi）ii）将步骤i）中确定的表达水平（ELi）与预定参考水平（ELRi）进行比较iii）计算 HADMS得分低于下式（I），其中如果基因Gi（ELi）的表达高于预定的参考水平（ELRi）或Ci = - ，则βi表示基因Gi的回归β系数参考值，Ci = 如果基因（ELi）的表达低于或等于预定参考水平（ELRi），则为1）iv）将在步骤iii）确定的得分HADMS与预定参考值HADMSR v进行比较）并且得出结论，当HADMS评分高于预定参考值HADMSR时，患者将对组合治疗做出响应，或者推断当HADMS得分低于预定参考值HADMSR时患者不会对组合治疗做出响应。

7. 发明授权

EP2904108B1 METHODS FOR PREDICTING MULTIPLE MYELOMA TREATMENT RESPONSE 有权
公开(公告)号：EP2904108B1
公开(公告)日：2019-05-22
申请号：EP13773791.2
申请日：2013-10-08
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , UNIVERSITE DE MONTPELLIER , Centre Hospitalier Universitaire de Montpellier
发明人： MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号： C12Q1/6886

8. 发明公开

EP2904108A1 METHODS FOR PREDICTING MULTIPLE MYELOMA TREATMENT RESPONSE 有权
标题翻译： VERFAHREN ZUR VORHERSAGE DER BEHANDLUNGSREAKING AUF DAS MULTIPLE MYELOM
公开(公告)号：EP2904108A1
公开(公告)日：2015-08-12
申请号：EP13773791.2
申请日：2013-10-08
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , UNIVERSITE DE MONTPELLIER , Centre Hospitalier Universitaire de Montpellier
发明人： MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号： C12Q1/68 , A61K31/7068 , A61K31/165
CPC分类号： C12Q1/6886 , A61K31/165 , A61K31/185 , A61K31/19 , A61K31/4045 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16 , G06F19/20
摘要： The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein &bgr;i represent the regression &bgr; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will not respond to the HDACi when the HAS score is lower than the predeference value HASR HAS = ∑ i = 1 n  &bgr;  i × Ci ( I )
摘要翻译：本发明涉及一种检测骨髓瘤患者是否对组蛋白脱乙酰酶抑制剂（HDACi）有反应的方法，其包括：测定生物样品中选自表A中的若干基因G1-Gn的表达水平（ELi）从所述患者获得，将步骤i）中确定的表达水平（ELi）与预定参考水平（ELRi）进行比较; iii）通过以下公式计算HAS评分，其中＆bgr; i表示回归＆bgr; 如果基因Gi（ELi）的表达高于预定参考水平（ELRi），则基因Gi和Ci的系数参考值如果基因（ELi）的表达低于或等于将预定参考水平（ELRi）与步骤iii）中确定的得分HAS与预定参考值HASR v进行比较，并得出当HAS得分高于预定参考值HASR时，患者将响应于HDACi，或者得出结论：当HAS评分低于预防值HASR HAS =Σi = 1时，患者不会响应HDACi。（i）

9. 发明申请

WO2022223488A1 USE OF SPLICE SWITCHING OLIGONUCLEOTIDES FOR EXON SKIPPING-MEDIATED KNOCKDOWN OF PIM2 审中-公开
公开(公告)号：WO2022223488A1
公开(公告)日：2022-10-27
申请号：PCT/EP2022/060187
申请日：2022-04-15
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ETABLISSEMENT FRANÇAIS DU SANG (EFS) , UNIVERSITÉ DE LIMOGES , UNIVERSITÉ DE MONTPELLIER , UNIVERSITÉ DE RENNES 1
发明人： FEST, Thierry , DELPY, Laurent , HAAS, Marion , MARCHALOT, Anne , LACOMBE, Gersende , MOREAUX, Jérôme
IPC分类号： C12N15/113
摘要： PIM2 kinase deregulation has been reported in several cancers. In particular, PIM2 is considered in multiple myeloma as part of the oncogenic process and several PIM kinase inhibitors have been developed showing encouraging results in preclinical studies and clinical trials. Now the inventors have developed an antisense RNA strategy based on a splice-switching oligonucleotide (SSO) so as to induce efficient knockdown of PIM2 expression. This SSO-mediated knockdown is a powerful approach to for cancer treatments. Accordingly, the present invention relates to the use of splice switching oligonucleotides for exon skipping-mediated knockdown of PIM2.

10. 发明申请

WO2014044848A1 METHODS FOR PREDICTING MULTIPLE MYELOMA TREATMENT RESPONSE 审中-公开
标题翻译：预测多发性骨髓瘤治疗反应的方法
公开(公告)号：WO2014044848A1
公开(公告)日：2014-03-27
申请号：PCT/EP2013/069736
申请日：2013-09-23
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE MONTPELLIER I , CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
发明人： MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号： C12Q1/68 , A61K31/7068
CPC分类号： C12Q1/6886 , A61K31/706 , A61K31/7068 , C12Q2600/106 , C12Q2600/158 , G06F19/20 , G06F19/3456
摘要： The present invention relates to a method of testing whether a patient suffering of multiple myeloma will respond or not to a DNA methyltransferase inhibitor (DNMTi) comprising: i. determining the expression level (ELi) of several genes G I -G n selected from table A in a biological sample obtained from said patient ii. comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii. calculating the DMS score trough the following formula (I) wherein βί represent the regression β coefficient reference value for the gene G i and Ci = 1 if the expression of the gene G i (ELi) is higher than the predetermined reference level (ELRi) or Ci = -1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score DMS determined at step iii) with a predetermined reference value DMS R and concluding that the patient will respond to the DNMTi when the DMS score is higher than the predetermined reference value DMS R or concluding that the patient will not respond to the DNMTi when the DMS score is lower than the predetermined reference value DMS R .
摘要翻译：本发明涉及测试患有多发性骨髓瘤的患者是否对DNA甲基转移酶抑制剂（DNMTi）有反应的方法，该方法包括：i。确定从所述患者ii获得的生物样品中选自表A中的若干基因GI-Gn的表达水平（ELi）。将步骤i）中确定的表达水平（ELi）与预定参考水平（ELRi）iii进行比较。通过以下公式（I）计算DMS分数，其中＆bgr;＆iacgr; 代表回归如果基因Gi（ELi）的表达高于预定参考水平（ELRi），则基因Gi和Ci的系数参考值如果基因（ELi）的表达低于或等于将预定参考水平（ELRi）与步骤iii）确定的得分DMS与预定参考值DMSR进行比较，并得出当DMS得分高于预定参考值DMSR时患者将响应于DNMTi，或得出患者当DMS分数低于预定参考值DMSR时，不会响应DNMTi。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式